Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled
study is to demonstrate as a proof of concept that early treatment with canakinumab prevents
progressive heart and respiratory failure in patients with COVID-19 infection. These results
will lead to and inform a Phase III randomized placebo-controlled trial.